Therapeutic Misconception in ALS

A Neuroethics Seminar
ALS neuroethics lecture

Twitter: @HMSBioethics #neuroethx
Be notified of the next event: http://bit.ly/1IswvA9
About the series: http://bit.ly/1KEzG9s

About this seminar 

Some subjects who participate in trials of novel therapies mistakenly believe that the trial is designed in a way to maximize benefit to the individual subjects—thus laboring under the Therapeutic Misconception. Patients with ALS have a uniformly fatal disease, and one might worry that ALS patients are even more prone to the therapeutic misconception.

Watch as our speakers discuss the evidence for a therapeutic misconception in ALS trials, and consider more broadly how the therapeutic misconception should be addressed by investigators and institutional review boards.

Panel

Scott Kim, MD, PhD Department of Bioethics, National Institutes of Health

James D. Berry, MD, MPH Unit Chief, ALS Multidisciplinary Clinic, Massachusetts General Hospital

Spencer Hey, PhD, Research Fellow, Brigham and Women's Hospital Instructor, Center for Bioethics Harvard Medical School